跳至主要内容
临床试验/NCT01788683
NCT01788683已完成不适用

A Randomized Controlled Trial of Regenexx™ SD Versus Exercise Therapy for Treatment of Non-retracted Supraspinatus Tendon Tears

Regenexx, LLC1 个研究点 分布在 1 个国家目标入组 51 人开始时间: 2013年2月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Regenexx, LLC
入组人数
51
试验地点
1
主要终点
DASH Score Change from Baseline

研究概览

简要总结

The primary objective of this study is to compare the improvement in subject-reported clinical outcomes, for Regenexx SD treatment vs. Exercise Therapy of non-retracted supraspinatus tendon tears, from baseline to 3 months, with continued evaluation of efficacy and durability up to 24 months.

Secondary objectives include evaluation of US evidence of tendon repair; incidence of post-operative complications, adverse events, re-injections, and surgical intervention; change in pain score and use of pain medications.

详细描述

Prospective, randomized, controlled to include 34 subjects treated with Regenexx SD and 17 subjects treated with Exercise Therapy alone (2:1 randomization).

Subjects will have a non-retracted supraspinatus tendon tear comprising at least one half the tendon thickness in the anterior-posterior and/or superior-inferior planes as evidenced with positive diagnostic imaging such as arthrogram, ultrasound and/or MR.

Subjects will be enrolled within 60 days prior to Regenexx-SD injection or initiation of exercise therapy and take part in follow-up visits for two years following treatment. A preoperative visit will occur at the time of enrollment; follow-up visits will occur at the clinical site at 6 weeks, 3 months, 6 months, 12 months, and 24 months post injection.

The primary endpoint analysis will be conducted once all subjects reach the 3 month endpoint. At that point, subjects enrolled in the Exercise Therapy group will be given the option of crossing over to the Regenexx SD treatment groups. Subjects will continue to be followed through the 2 year endpoint with data analysis performed at the 1 year and 2 year time points.

Subjects will complete the study following the 2 year follow-up visit.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Physical examination consistent with Rotator Cuff tear
  • •Unremitting pain in the affected shoulder for at least 3 months
  • •Significant functional disability related to pain, lack of strength, or other shoulder symptoms
  • •Positive diagnostic imaging, which may include arthrogram, ultrasound and/or MR, on the affected shoulder indicating a non-retracted supraspinatus tendon tear comprising at least one half the tendon thickness in the anterior-posterior and/or superior-inferior planes
  • •Reasonable movement of the non-treated arm, defined as a shoulder elevation of equal or more than 90°, and able to perform (post-injection) exercises
  • •Is independent, ambulatory, and can comply with all post-operative evaluations and visits

排除标准

  • •A massive rotator cuff tear as demonstrated by Grade 3 or less muscle strength on testing internal and external rotation of the affected shoulder
  • •Previous surgery to the affected shoulder
  • •Concomitant tears of biceps tendons
  • •Grade 2 or greater SLAP tear
  • •Type 3 acromion
  • •Significant bone spur in subacromial space
  • •Inflammatory or auto-immune based joint diseases or other upper extremity pathology (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, polymyalgia, polymyositis, gout pseudogout)
  • •Quinolone or Statin induced myopathy/ tendinopathy
  • •Kellgren-Lawrence grade 2 or greater glenohumeral osteoarthritis
  • •Adhesive capsulitis (mild or severe)
  • •Symptomatic cervical spine pathology (e.g. radicular cervical pain)
  • •Severe neurogenic inflammation of the cutaneous nerves about the shoulder
  • •Shoulder instability requiring surgical stabilization
  • •Contraindications for MRI
  • •Tested positive or has been treated for a malignancy in the past or is suspected of having a malignancy or is currently undergoing radiation or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed injection site
  • •Condition represents a worker's compensation case
  • •Currently involved in a health-related litigation procedure
  • •Is pregnant
  • •Bleeding disorders
  • •Currently taking anticoagulant or immunosuppressive medication
  • •Use of chronic opioid

研究组 & 干预措施

Exercise Therapy

Active Comparator

Subjects will be instructed in a set of appropriate rotator cuff strengthening exercises and given an instructional hand-out to take home.

干预措施: Exercise Therapy (Other)

Regenexx SD

Active Comparator

Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged tendon.

干预措施: Regenexx SD (Procedure)

结局指标

主要结局

DASH Score Change from Baseline

时间窗: Change from Baseline to 3 months

The primary endpoint for this study is the difference between treatment groups in the within patient mean change from baseline to 3 months in Disabilities of the Arm Shoulder and Hand (DASH) scores.

次要结局

  • Mean Pain Scales(3, 6, 12 and 24 months)
  • Mean DASH scores(6, 12 and 24 months)
  • Incidence of re-injection and surgical revision(24 months)
  • Incidence of Complications and Adverse Events(24 months)
  • MRI evidence of tendon repair(12 months)

研究者

发起方
Regenexx, LLC
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验